26 Patients Randomized

A Phase I/II Acne study site working in connection with the University of Pennsylvania faced a patient identification challenge common to research sites at every size: the existing referral network could not sustain the pace the protocol required.

In-house outreach had been considered but not resourced. Commercially available recruitment vendors offered campaign deliverables tied to activity, not to the outcome the site needed: randomized patients. The cost structure made no distinction between campaigns that succeeded and campaigns that didn't.

The site required a partner whose financial commitment matched the commitment the site was making to the sponsor.

The campaign delivered 26 randomized patients against a $15,000 investment, a cost per randomized patient of $577.

Per-patient site fees for Phase I/II studies typically range from $5,000 to $15,000 per randomized patient. At an estimated $5,000 to $15,000 per-patient site fee, 26 randomized patients represents a potential $130,000 to $390,000 in patient revenue against a $15,000 campaign investment.

The randomization commitment in Clinical Enroll's contract meant the site carried no financial exposure if the campaign fell short. The contractual structure was designed around the outcomes the site could report to its sponsor and account for on its own P&L.